Shares of iCAD, Inc. (NASDAQ:ICAD - Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.50 and traded as high as $2.05. iCAD shares last traded at $1.93, with a volume of 208,366 shares traded.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised iCAD from a "sell" rating to a "hold" rating in a research note on Thursday, August 22nd.
Read Our Latest Research Report on iCAD
iCAD Stock Performance
The firm has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.50. The company has a market cap of $50.43 million, a PE ratio of -15.83 and a beta of 1.50.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The technology company reported ($0.07) earnings per share for the quarter. iCAD had a negative net margin of 15.67% and a negative return on equity of 13.59%. The company had revenue of $5.03 million during the quarter.
Hedge Funds Weigh In On iCAD
Several hedge funds and other institutional investors have recently modified their holdings of the company. AMH Equity Ltd acquired a new position in shares of iCAD during the 1st quarter valued at $207,000. First Eagle Investment Management LLC lifted its stake in shares of iCAD by 3.2% during the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company's stock worth $1,129,000 after purchasing an additional 22,000 shares in the last quarter. Perritt Capital Management Inc. boosted its position in shares of iCAD by 7.5% in the first quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company's stock worth $225,000 after buying an additional 9,717 shares during the period. Virtu Financial LLC grew its stake in shares of iCAD by 55.6% in the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company's stock valued at $34,000 after buying an additional 7,604 shares in the last quarter. Finally, Perritt Capital Management Inc raised its holdings in shares of iCAD by 14.2% during the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company's stock valued at $208,000 after buying an additional 19,917 shares during the period. 24.61% of the stock is owned by institutional investors and hedge funds.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
